CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2017

Primary Completion Date

May 17, 2022

Study Completion Date

January 1, 2026

Conditions

Breast Cancer Stage IIB

Interventions

DRUG

Hydroxychloroquine

DRUG

Everolimus

Trial Locations (1)

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors

lead

Abramson Cancer Center at Penn Medicine

OTHER